nach oben

Erschienen in:

28.11.2023 | Research

A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM)

verfasst von: Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, Glen H.J. Stevens, Hui-Kuo Shu, Tom Mikkelsen, Frank Lieberman, Glenn J. Lesser, Emerson Lee, Stuart A. Grossman

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A multi-site Phase I trial was conducted to determine the safety, maximum tolerated dose, and pharmacokinetics (PK) of Veliparib, a Poly (ADP-ribose) polymerase [PARP] enzyme inhibitor, when administered with temozolomide (TMZ) alone and then with temozolomide and radiation (RT) in patients with newly diagnosed glioblastoma.

Methods

Given the potential for myelosuppression when a PARP inhibitor is combined with chemotherapy, the first 6 patients accrued were given Veliparib 10 mg bid and TMZ 75 mg/m2/d daily for six weeks. If this was well tolerated, the same doses of Veliparib and TMZ would be tested along with standard radiation with plans to dose escalate the Veliparib in subsequent patient cohorts. Once a maximal tolerated dose was determined, a 78 patient phase II study was planned. Peripheral blood pharmacokinetics were assessed.

Results

Twenty-four patients were enrolled. In the first 6 patients who received 6 weeks of TMZ with Veliparib only one dose limiting toxicity (DLT) occurred. The next 12 patients received 6 weeks of RT + TMZ + veliparib and 4/12 (33%) had dose limiting hematologic toxicities. As a result, Veliparib was reduced by 50% to 10 mg BID every other week, but again 3/3 patients had dose limiting hematologic toxicities. The trial was then terminated. The mean clearance (± SD) CL/F of Veliparib for the initial dose (27.0 ± 9.0 L/h, n = 16) and at steady-state for 10 mg BID (23.5 ± 10.4 L/h, n = 18) were similar. Accumulation for BID dosing was 56% (± 33%).

Conclusions

Although Veliparib 10 mg BID administered with TMZ 75 mg/m2 for six weeks was well tolerated, when this regimen was combined with standard partial brain irradiation it was severely myelosuppressive even when the dose was reduced by 50%. This study again highlights the potential of localized cranial radiotherapy to significantly increase hematologic toxicity of marginally myelosuppressive systemic therapies.

CHAMBON P, WEILL JD, MANDEL P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43. https://doi.org/10.1016/0006-291x(63)90024-xCrossRefPubMed

Chen A (2011) PARP inhibitors: its role in treatment of cancer. Chin J Cancer 30:463–471. https://doi.org/10.5732/cjc.011.10111CrossRefPubMedPubMedCentral

Li W, Wang F, Song G, Yu Q, Du R, Xu P (2023) PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities. Front Pharmacol 14:1198948. https://doi.org/10.3389/fphar.2023.1198948CrossRefPubMedPubMedCentral

Shall S, de Murcia G (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460:1–15. https://doi.org/10.1016/s0921-8777(00)00016-1CrossRefPubMed

Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375–429. https://doi.org/10.1124/pr.54.3.375CrossRefPubMed

Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, Tsutsumi M, Sugimura T (2000) The response of parp knockout mice against DNA damaging agents. Mutat Res 462:159–166. https://doi.org/10.1016/s1383-5742(00)00033-8CrossRefPubMed

Herrmann GK, Yin YW (2023) The role of poly(ADP-ribose) polymerase 1 in Nuclear and mitochondrial base excision repair. Biomolecules 13:1195. https://doi.org/10.3390/biom13081195CrossRefPubMedPubMedCentral

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JCG, Kirkby KJ, Kirkby NF (2013) Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8:65–65. https://doi.org/10.1186/1748-717X-8-65CrossRefPubMedPubMedCentral

Tisdale MJ (1987) Antitumor imidazotetrazines–XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457–462. https://doi.org/10.1016/0006-2952(87)90351-0CrossRefPubMed

10.

Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045–9051. https://doi.org/10.1021/bi00197a003CrossRefPubMed

11.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. 352/10/997 [pii]CrossRefPubMed

12.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA et al (2018) ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE 13:e0202860. https://doi.org/10.1371/journal.pone.0202860CrossRefPubMedPubMedCentral

13.

Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA (2021) PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol 23:920–931. https://doi.org/10.1093/neuonc/noab003CrossRefPubMedPubMedCentral

14.

Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G (2002) Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 40:44–54. https://doi.org/10.1002/glia.10113CrossRefPubMed

15.

Barazzuol L, Jena R, Burnet NG, Jeynes JCG, Merchant MJ, Kirkby KJ, Kirkby NF (2012) In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res 177:651–662. https://doi.org/10.1667/rr2803.1CrossRefPubMed

16.

Lesueur P, Chevalier F, Austry J, Waissi W, Burckel H, Noel G, Habrand J, Saintigny Y, Joly F (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8:69105–69124. https://doi.org/10.18632/oncotarget.19079CrossRefPubMedPubMedCentral

17.

Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N (2023) PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. https://doi.org/10.1038/s41416-023-02326-7CrossRefPubMedPubMedCentral

18.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL et al (2019) Veliparib with First-Line Chemotherapy and as maintenance therapy in Ovarian Cancer. N Engl J Med 381:2403–2415. https://doi.org/10.1056/NEJMoa1909707CrossRefPubMedPubMedCentral

19.

Han HS, Dieras V, Robson M, Palacova M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML et al (2018) Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic Breast cancer: randomized phase II study. Ann Oncol 29:154–161. https://doi.org/10.1093/annonc/mdx505CrossRefPubMed

20.

Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub J, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced Breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282. https://doi.org/10.1016/S1470-2045(20)30447-2CrossRefPubMed

21.

Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA (2021) Veliparib and Nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell Lung cancer: a phase 1 dose escalation study. Lung Cancer 161:180–188. https://doi.org/10.1016/j.lungcan.2021.09.004CrossRefPubMed

22.

Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D et al (2019) A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced Pancreatic cancer. EBioMedicine 40:375–381. https://doi.org/10.1016/j.ebiom.2018.12.060CrossRefPubMedPubMedCentral

23.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W et al (2017) Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. Lancet Gastroenterol Hepatol 2:418–426. https://doi.org/10.1016/S2468-1253(17)30012-2CrossRefPubMed

24.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical Tumor models. Clin Cancer Res 13:2728–2737. https://doi.org/10.1158/1078-0432.CCR-06-3039CrossRefPubMed

25.

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705–2711. https://doi.org/10.1200/JCO.2008.19.7681CrossRefPubMedPubMedCentral

26.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. 352/10/987 [pii]CrossRefPubMed

27.

Malanga M, Althaus FR (2005) The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 83:354–364. https://doi.org/10.1139/o05-038CrossRefPubMed

28.

Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de Murcia G (1999) Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81:69–75. https://doi.org/10.1016/s0300-9084(99)80040-6CrossRefPubMed

29.

Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z et al (2004) Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10:881–889. https://doi.org/10.1158/1078-0432.ccr-1144-3CrossRefPubMed

30.

Wang C, Li J (2021) Haematologic toxicities with PARP inhibitors in cancer patients: an uptodate metaanalysis of 29 randomized controlled trials. J Clin Pharm Ther 46:571–584. https://doi.org/10.1111/jcpt.13349CrossRefPubMed

31.

Farres J, Llacuna L, Martin-Caballero J, Martinez C, Lozano JJ, Ampurdanes C, Lopez-Contreras AJ, Florensa L, Navarro J, Ottina E et al (2015) PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ 22:1144–1157. https://doi.org/10.1038/cdd.2014.202CrossRefPubMed

32.

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM et al (2016) A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126:309–316. https://doi.org/10.1007/s11060-015-1966-zCrossRefPubMed

33.

Sim H, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, Koh E, Back M, Wheeler H, Sulman EP et al (2021) A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol 23:1736–1749. https://doi.org/10.1093/neuonc/noab111CrossRefPubMedPubMedCentral

34.

Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Mashru SH, Piccioni DE, Friday BEB, Dixon JG, Kabat B et al (2022) Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102). JCO 40:2001. https://doi.org/10.1200/JCO.2022.40.16_suppl.2001CrossRef

35.

Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H et al (2015) Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol 122:409–417. https://doi.org/10.1007/s11060-015-1733-1CrossRefPubMed

36.

Mittapalli RK, Nuthalapati S, Delke DeBord AE, Xiong H (2017) Development of a level A in Vitro-in vivo correlation for Veliparib (ABT-888) extended Release Tablet Formulation. Pharm Res 34:1187–1192. https://doi.org/10.1007/s11095-017-2133-3CrossRefPubMed

37.

Nuthalapati S, Munasinghe W, Giranda V, Xiong H (2018) Clinical pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in subjects with nonhematologic malignancies. Clin Pharmacokinet 57:51–58. https://doi.org/10.1007/s40262-017-0547-zCrossRefPubMed

38.

Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J et al (2019) Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemother Pharmacol 83:319–328. https://doi.org/10.1007/s00280-018-3731-4CrossRefPubMed

39.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM et al (2017) A phase 1 study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 23:697–706. https://doi.org/10.1158/1078-0432.CCR-16-0984CrossRefPubMed

40.

Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM et al (2015) Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic Melanoma. Ann Oncol 26:2173–2179. https://doi.org/10.1093/annonc/mdv308CrossRefPubMed

41.

Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M (1999) The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 44:535–543. https://doi.org/10.1016/s0360-3016(99)00060-7CrossRefPubMed

42.

Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E (2013) The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 31:140–144. https://doi.org/10.3109/07357907.2012.762780CrossRefPubMedPubMedCentral

43.

Kleinberg L, Sloan L, Grossman S, Lim M (2019) Radiotherapy, Lymphopenia, and host Immune Capacity in Glioblastoma: a potentially actionable toxicity Associated with reduced efficacy of Radiotherapy. Neurosurgery 85:441–453. https://doi.org/10.1093/neuros/nyz198CrossRefPubMed

44.

Paganetti H (2023) A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol 13:1201500. https://doi.org/10.3389/fonc.2023.1201500CrossRefPubMedPubMedCentral

45.

Kut C, Kleinberg L (2023) Radiotherapy, Lymphopenia and improving the outcome for glioblastoma: a narrative review. Chin Clin Oncol 12:4–94. https://doi.org/10.21037/cco-22-94CrossRefPubMed

46.

Campian JL, Piotrowski AF, Ye X, Hakim FT, Rose J, Yan X, Lu Y, Gress R, Grossman SA (2017) Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. J Neurooncol 135:343–351. https://doi.org/10.1007/s11060-017-2580-zCrossRefPubMed

47.

Hughes MA, Parisi M, Grossman S, Kleinberg L (2005) Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of Infection. Int J Radiat Oncol Biol Phys 62:1423–1426. https://doi.org/10.1016/j.ijrobp.2004.12.085CrossRefPubMed

Titel: A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM)
verfasst von: Lawrence Kleinberg
Xiaobu Ye
Jeff Supko
Glen H.J. Stevens
Hui-Kuo Shu
Tom Mikkelsen
Frank Lieberman
Glenn J. Lesser
Emerson Lee
Stuart A. Grossman
Publikationsdatum: 28.11.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04514-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat

Incidental meningiomas: a current and increasingly common challenge

Anatomical changes in resection cavity during brain radiotherapy